A61P 27 - Drugs for disorders of the senses

Patents for A61P 27 - Drugs for disorders of the senses (53,017)
11/2002
11/28/2002	US20020177608 Polymorphs of fexofenadine hydrochloride
11/28/2002	US20020177587 Treating sexual dysfunction including erectile dysfunction, diabetes melitus, gastrointestinal disorders, including gastric paresis and cardiovascular disorders; cyclic guanosine 3',5'-monophosphate (cGMP)
11/28/2002	US20020177586 Method for treating fibrotic diseases or other indications ID
11/28/2002	US20020177213 Tissue plasminogen activator-like protease
11/28/2002	US20020176885 Given concentration of halide-comprising salts such as sodium chloride; nonirritating antiseptic; can be used in eyes
11/28/2002	CA2448076A1 3-quinoline-2-(1h)-ylideneindolin-2-one derivatives
11/28/2002	CA2447918A1 Method of treating dry eye disorders
11/28/2002	CA2447883A1 Use of nf-kappa-b inhibitors to treat dry eye disorders
11/28/2002	CA2447231A1 Methods for inhibiting angiogenesis
11/28/2002	CA2447023A1 Conjugates activated by cell surface proteases and therapeutic uses thereof
11/28/2002	CA2447020A1 The use of 4-aminopyridine derivatives for the treatment of mglur5 receptor mediated diseases
11/28/2002	CA2446734A1 Antibodies against tumor necrosis factor delta (april)
11/28/2002	CA2445631A1 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same
11/28/2002	CA2444955A1 Inactivation of genes of the mep pathway
11/28/2002	CA2441801A1 Methods and formulations for increasing the affinity of a1 adenosine receptor ligands for the a1 adenosine receptor
11/27/2002	EP1260587A2 Tyrosyl tRNA synthetase
11/27/2002	EP1260232A1 Remedies for malignant tumor-concomitant neurosis and azoor or analogous diseases thereof
11/27/2002	EP1260231A1 Drugs for ameliorating retinal function
11/27/2002	EP1260227A1 Lipoteichoic acid from lactic acid bacteria and its use to modulate immune responses mediated by gram-negative bacteria, potential pathogenic gram-positive bacteria
11/27/2002	EP1259648A2 Diagnostics and therapeutics for glaucoma
11/27/2002	EP1259615A1 Human antibodies against eotaxin and their use
11/27/2002	EP1259612A2 G-protein coupled receptor related polypeptides
11/27/2002	EP1259611A2 G-protein coupled receptors
11/27/2002	EP1259605A2 Mutated cyclin g1 protein
11/27/2002	EP1259595A2 Integrin antagonists
11/27/2002	EP1259548A1 Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis
11/27/2002	EP1259527A1 35 human secreted proteins
11/27/2002	EP1259505A2 Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same
11/27/2002	EP1259504A1 Pyrazole ether derivatives as anti-inflammatory/analgesic agents
11/27/2002	EP1259494A1 Aryloxyacetic acids for diabetes and lipid disorders
11/27/2002	EP1259488A1 Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors
11/27/2002	EP1259487A1 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
11/27/2002	EP1259477A1 Aminoadamantane derivatives as therapeutic agents
11/27/2002	EP1259282A1 Method and apparatus for transcutaneous infusion of carbon dioxide for local relief of pain and other ailments
11/27/2002	EP1259236A1 Tyrosine kinase inhibitors
11/27/2002	EP1259235A1 Tyrosine kinase inhibitors
11/27/2002	EP1259233A1 Modulation of bone formation
11/27/2002	EP1259223A1 Protein matrix materials, devices and methods of making and using thereof
11/27/2002	EP0920330B1 hCG AND DERIVATIVES AS MATRIX METALLOPROTEASES INHIBITORS
11/27/2002	EP0777471B1 Inhibition of leukotriene biosynthesis with urea derivatives
11/27/2002	EP0627933B1 Bystander suppression of autoimmune diseases
11/27/2002	CN1382144A Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of P38 protein kinase
11/27/2002	CN1382143A Inhibitors of alpha L beta 2 mediated cell adhesion
11/27/2002	CN1382134A Benzopyranyl guanidine derivtives, process for preparation thereof and pharmaceutical compositions containing them
11/27/2002	CN1382121A C16 unsaturated FP-selective prostaglandins analogs
11/27/2002	CN1382119A Substituted alpha hydroxy acid aspertate specific cysteine protease inhibitors and use thereof
11/27/2002	CN1382057A Treatment of conjunctivitis
11/27/2002	CN1382052A Use of dipyridazole or mopidamol in the manufacture of a medicament for treatment and prevention of fibrin-dependent microcirculation disorders
11/27/2002	CN1382046A Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use
11/27/2002	CN1382044A Use of cell factor inhibiting anti-inflammatory agent in rhinovirus infection
11/26/2002	US6486305 Method of modulating the efficiency of translation termination and degradation of aberrant mrna involving a surveillance complex comprising human upf1p, eucaryotic release factor 1 and eucaryotic release factor 3
11/26/2002	US6486212 Semifluorinated alkanes and the use thereof
11/26/2002	US6486208 Sustained release, and comfortable opthalmic composition and method for ocular therapy
11/26/2002	US6486190 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
11/26/2002	US6486186 Thiazole compounds as cyclic AMP-specific phosphodiesterase inhibitors and method of using the same
11/26/2002	US6486139 Ophthalmic solution comprising glycogen
11/26/2002	US6486138 Ophthalmic compositions containing galactomannan polymers and borate
11/26/2002	US6486122 Methods of increasing body weight in a subject by administering TGF-α
11/26/2002	US6485755 Methods of using electron active compounds for managing cancer
11/21/2002	WO2002092781A2 Peptide compounds for counteracting reactive oxygen species and free radicals
11/21/2002	WO2002092759A2 Molecules for disease detection and treatment
11/21/2002	WO2002092625A2 Moraxella(branhamella) catarrhalis antigens
11/21/2002	WO2002092597A1 The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.0?2,11.04.9¿)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
11/21/2002	WO2002092588A2 Aromatic sulfone hydroxamates and their use as protease inhibitors
11/21/2002	WO2002092553A1 Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
11/21/2002	WO2002092099A1 Prostanoic acid derivatives as agents for lowering intraocular pressure
11/21/2002	WO2002092098A1 Method for treating ocular hypertension and glaucoma
11/21/2002	WO2002092089A1 Tartrate salts of 5,8,14-triazatetracyclo {10.3.1.0?2,11.04,9¿}-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
11/21/2002	WO2002092068A1 Carboxylic acid derivatives and drugs containing the same as the active ingredient
11/21/2002	WO2002092067A1 Compositions for transmucosal administration containing coenzyme q as the active ingredient
11/21/2002	WO2002092064A2 Therapeutic method for inducing tolerance
11/21/2002	WO2002092063A2 Utilization of rutins and aescins in the treatment of ocular circulatory disturbances
11/21/2002	WO2002092004A2 Use of hmg fragment as anti-inflammatory agents
11/21/2002	WO2002062343A3 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
11/21/2002	WO2002060340A9 Method for identifying maxi-k channel blockers
11/21/2002	WO2002049649A3 Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2)
11/21/2002	WO2002043785A3 Intraocular implants for preventing transplant rejection in the eye
11/21/2002	WO2002024226A8 Photosensitisers
11/21/2002	WO2002012250B1 Pyrazole-thiazole compounds, pharmaceutical compositions containing them, and methods of their use for inhibiting cyclin-dependent kinases
11/21/2002	WO2001042273A9 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
11/21/2002	US20020173661 Phosphodiesterase-4 (PDE4); thiazole-containing pyridine (N-oxide) compounds; 4-(2-(3,4-Bis(difluoromethoxy)phenyl)-2-(5-(2-(1-hydroxy-1 -methyl)ethyl)thiazolyl)ethyl)pyridine N-oxide for example
11/21/2002	US20020173646 Quinazoline derivatives and pharmaceutical compositions containing them
11/21/2002	US20020173516 Pharmaceutical compositions and methods for treating immune-response associated diseases of the surface and the anterior segment of the eye
11/21/2002	US20020173507 Antiproliferative agents; apoptosis; anticancer agents
11/21/2002	US20020173464 Modulation of pericyte proliferation
11/21/2002	US20020173460 Complexing with fibronectins; analyzing, calibration; antiinflammatory agents, respiratory system disorders
11/21/2002	US20020172999 Novel KIAA1061-like cell adhesion molecule-like proteins and polynucleotides encoding them
11/21/2002	DE10122715A1 Verwendung von Rutinen und Aescinen zur Behandlung aurikulärer Durchblutungsstörungen Use of rutins and Aescinen for treating auricular circulatory disorders
11/21/2002	DE10122714A1 Combination of a rutin and aescin for treating ocular disorders associated with altered blood circulation, e.g. glaucoma or edema
11/21/2002	CA2447576A1 Use of hmg fragment as anti-inflammatory agents
11/21/2002	CA2447292A1 Peptide compounds for counteracting reactive oxygen species and free radicals
11/21/2002	CA2447017A1 Moraxella(branhamella) catarrhalis antigens
11/21/2002	CA2446988A1 The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof
11/21/2002	CA2446740A1 Hydroxamic acids and acyl hydroxamines as naaladase inhibitors
11/21/2002	CA2446593A1 Carboxylic acid derivatives and pharmaceutical compositions comprising the same as an active ingredient
11/21/2002	CA2446586A1 Aromatic sulfone hydroxamates and their use as protease inhibitors
11/21/2002	CA2445366A1 Molecules for disease detection and treatment
11/21/2002	CA2444627A1 Method for treating ocular hypertension and glaucoma
11/21/2002	CA2443191A1 Compositions for transmucosal administration containing coenzyme q as the active ingredient
11/20/2002	EP1258474A2 Alkylamide compounds

1 ... 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 ... 531